Lactobacillus reuteri NCIMB 30242 and Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio

• Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial

  • 2012-09-19
  • RCT · n = 127
  • European Journal of Clinical Nutrition 66(11)
  • • M. L. Jones
    • C. Martoni
    • S. Prakash

  • PubMed: 22990854
  • DOI: 10.1038/ejcn.2012.126

  28 Insights on

  • Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio

  • High evidence
  • Highly Cited
  • Rigorous Journal

  apoB-100/apoA-1 ratio was reduced by 9.00% (P = 0.026) relative to placebo.

  Effect

  Beneficial

  Effect size

  Small

  Significant

  Yes

  Dose

  capsules (dose not specified in abstract)